MA33823B1 - Polythérapie pour bronchopneumopathie chronique obstructive (copd) - Google Patents

Polythérapie pour bronchopneumopathie chronique obstructive (copd)

Info

Publication number
MA33823B1
MA33823B1 MA34966A MA34966A MA33823B1 MA 33823 B1 MA33823 B1 MA 33823B1 MA 34966 A MA34966 A MA 34966A MA 34966 A MA34966 A MA 34966A MA 33823 B1 MA33823 B1 MA 33823B1
Authority
MA
Morocco
Prior art keywords
preparation
copd
formoterol
combined treatment
glycopyrronium bromide
Prior art date
Application number
MA34966A
Other languages
Arabic (ar)
English (en)
Inventor
Sauro Bonelli
Francesca Usberti
Enrico Zambelli
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42107420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33823(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of MA33823B1 publication Critical patent/MA33823B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B3/04—Methods of, or means for, filling the material into the containers or receptacles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B31/00—Packaging articles or materials under special atmospheric or gaseous conditions; Adding propellants to aerosol containers
    • B65B31/003—Adding propellants in fluid form to aerosol containers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B7/00—Closing containers or receptacles after filling
    • B65B7/16—Closing semi-rigid or rigid containers or receptacles not deformed by, or not taking-up shape of, contents, e.g. boxes or cartons
    • B65B7/28—Closing semi-rigid or rigid containers or receptacles not deformed by, or not taking-up shape of, contents, e.g. boxes or cartons by applying separate preformed closures, e.g. lids, covers
    • B65B7/2842—Securing closures on containers
    • B65B7/285—Securing closures on containers by deformation of the closure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Mechanical Engineering (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)

Abstract

L'invention concerne une préparation aérosol conçue pour être administrée à des patients atteints de bronchopneumopathie chronique obstructive au moyen d'un aérosol doseur sous pression (pmdi), laquelle préparation comprend du bromure de glycopyrronium combinà du formotérol. La préparation comprend également un propulseur hfa, un co-solvant et une quantité d'acide inorganique suffisante pour stabiliser à la fois les composé de bromure de glycopyrronium et de formotérol. éventuellement, la préparation comprend également du dipropionate de béclométasone.
MA34966A 2009-12-23 2012-06-14 Polythérapie pour bronchopneumopathie chronique obstructive (copd) MA33823B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09180671 2009-12-23
PCT/EP2010/070479 WO2011076843A2 (fr) 2009-12-23 2010-12-22 Polythérapie pour bronchopneumopathie chronique obstructive (copd)

Publications (1)

Publication Number Publication Date
MA33823B1 true MA33823B1 (fr) 2012-12-03

Family

ID=42107420

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34966A MA33823B1 (fr) 2009-12-23 2012-06-14 Polythérapie pour bronchopneumopathie chronique obstructive (copd)

Country Status (40)

Country Link
US (3) US20110150782A1 (fr)
EP (1) EP2515855B3 (fr)
JP (2) JP5914354B2 (fr)
KR (2) KR20170040392A (fr)
CN (2) CN102665679B (fr)
AR (2) AR079726A1 (fr)
AU (3) AU2010334859A1 (fr)
BR (1) BR112012015337B8 (fr)
CA (1) CA2785321C (fr)
CL (1) CL2012001705A1 (fr)
CO (1) CO6541628A2 (fr)
CY (2) CY1115116T1 (fr)
DK (1) DK2515855T6 (fr)
EA (2) EA027778B1 (fr)
ES (1) ES2468840T7 (fr)
FI (2) FI2515855T6 (fr)
GE (1) GEP20156311B (fr)
HR (1) HRP20140582T4 (fr)
HU (1) HUS1800001I1 (fr)
IL (1) IL260932B (fr)
LT (1) LTC2515855I2 (fr)
LU (1) LUC00060I2 (fr)
MA (1) MA33823B1 (fr)
MX (1) MX2012006878A (fr)
MY (1) MY156949A (fr)
NL (1) NL300923I2 (fr)
NO (1) NO2018001I2 (fr)
NZ (1) NZ600790A (fr)
PE (2) PE20160853A1 (fr)
PH (1) PH12012501066A1 (fr)
PL (1) PL2515855T6 (fr)
PT (1) PT2515855E (fr)
RS (1) RS53391B2 (fr)
SG (1) SG181868A1 (fr)
SI (1) SI2515855T1 (fr)
TN (1) TN2012000269A1 (fr)
TW (1) TWI495468B (fr)
UA (1) UA113832C2 (fr)
WO (1) WO2011076843A2 (fr)
ZA (1) ZA201204615B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012015334A2 (pt) * 2009-12-23 2016-03-15 Chiesi Farma Spa terapia combinada para doença pulmonar obstrutiva crônica
SG181870A1 (en) 2009-12-23 2012-07-30 Chiesi Farma Spa Aerosol formulation for copd
EP2515855B3 (fr) * 2009-12-23 2023-05-03 Chiesi Farmaceutici S.p.A. Polythérapie pour la COPD
CN103501776A (zh) * 2011-02-17 2014-01-08 西普拉有限公司 甘罗铵与β2激动剂的组合物
TWI597072B (zh) * 2011-10-11 2017-09-01 吉斯藥品公司 包覆脂肪酸的β－致效劑之結晶微粒
BR112015006571A2 (pt) * 2012-10-23 2017-07-04 Cipla Ltd composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição farmacêutica, e, método para a profilaxia ou tratamento de asma, doença pulmonar obstrutiva crônica e distúrbios respiratórios relacionados
RS57799B1 (sr) 2013-07-11 2018-12-31 Chiesi Farm Spa Formulacija suvog praha za administriranje inhalacijom, koja obuhvata atniholinergik, kortikosteroid i beta-adrenergik
RS57687B1 (sr) 2013-12-30 2018-11-30 Chiesi Farm Spa Pod pritiskom stabilan aerosolni rastvor kompozicije glikopironijum bromida i kombinacije formoterola
GEAP201814192A (en) * 2013-12-30 2018-02-26 Chiesi Farm Spa Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
US11039621B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039620B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US9622483B2 (en) 2014-02-19 2017-04-18 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US9554992B2 (en) 2014-06-09 2017-01-31 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
GB201416909D0 (en) * 2014-09-25 2014-11-12 Prosonix Ltd Method of forming concentrated solution
US20160310410A1 (en) 2015-04-24 2016-10-27 Glenmark Specialty S.A. Pharmaceutical compositions comprising arformoterol and glycopyrronium
SI3377108T1 (sl) 2015-11-16 2020-05-29 Chiesi Farmaceutici S.P.A. Postopek za pripravo suhe praškaste formulacije, ki obsega antiholinergik, kortikosteroid in beta-adrenergik
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
MA43782A (fr) 2016-03-31 2021-04-28 Chiesi Farm Spa Dispositif d'inhalation d'aérosol
US10098837B2 (en) 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
WO2018051133A1 (fr) 2016-09-19 2018-03-22 Mexichem Fluor S.A. De C.V. Composition pharmaceutique
CN114712337A (zh) * 2016-09-19 2022-07-08 墨西哥氟石股份公司 药物组合物
GEP20217239B (en) * 2016-09-19 2021-03-25 Mexichem Fluor Sa De Cv Pharmaceutical composition
PL3621589T3 (pl) * 2017-05-11 2021-12-06 Chiesi Farmaceutici S.P.A. Sposób wytwarzania preparatu suchego proszku obejmującego środek antycholinergiczny, kortykosteroid i środek beta-adrenergiczny
US10786450B2 (en) 2017-05-11 2020-09-29 Chiesi Farmaceutici S.P.A. Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
AU2019282562A1 (en) * 2018-06-04 2021-01-21 Lupin Inc. Stable pharmaceutical compositions for pressurized metered dose inhalers
AU2019477296A1 (en) * 2019-12-02 2022-04-14 Chiesi Farmaceutici S.P.A. Stainles steel can for pressurised metered dose inhalers
US20230270754A1 (en) 2020-07-31 2023-08-31 Chemo Research, S.L. Combination therapy for inhalation administration
US20230277451A1 (en) 2020-10-09 2023-09-07 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler
EP4531920A1 (fr) 2022-05-27 2025-04-09 Chiesi Farmaceutici S.p.A. Formulation pharmaceutique pour aérosol-doseur sous pression
EP4531921A1 (fr) 2022-05-27 2025-04-09 Chiesi Farmaceutici S.p.A. Formulation pharmaceutique pour aérosol-doseur sous pression
EP4531922A1 (fr) 2022-05-27 2025-04-09 Chiesi Farmaceutici S.p.A. Formulation pharmaceutique pour aérosol-doseur pressurisé

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
ATE177941T1 (de) 1992-12-09 1999-04-15 Boehringer Ingelheim Pharma Stabilisierte medizinische aerosollösungen
ES2234266T3 (es) 1998-07-24 2005-06-16 Jago Research Ag Formulaciones medicas para aerosoles.
JP4672143B2 (ja) * 1998-08-04 2011-04-20 ヤゴテック アーゲー 医薬用エーロゾル製剤
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
IT1317720B1 (it) 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
AU2000250701B2 (en) * 2000-05-22 2004-07-01 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurised metered dose inhalers
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
PT1372608E (pt) 2001-03-30 2008-01-04 Jagotec Ag Formulações de aerossol médicas
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
EP1321159A1 (fr) 2001-12-21 2003-06-25 CHIESI FARMACEUTICI S.p.A. Dispositif d'actionnement pour inhalateur doseur pressurisé avec orifices percés par laser
ES2342463T3 (es) 2002-03-01 2010-07-07 Chiesi Farmaceutici S.P.A. Formulacion superfina de formoterol.
CA2510043A1 (fr) 2002-12-16 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Formulations de solutions aux hfc contenant du tiotropium
AR041873A1 (es) * 2003-10-30 2005-06-01 Pablo Cassara Srl Lab Una formulacion farmaceutica en aerosol adecuada para la inhalacion oral o nasal que contienen glucocorticoides en solucion estable al almacenamiento; un metodo para estabilzar formulaciones y uso de un agente estabilizante
ES2309705T3 (es) * 2004-02-06 2008-12-16 MEDA PHARMA GMBH & CO. KG Nueva combinacion de anticolinergico y beta-mimeticos para el tratamiento de enfermedades respiratorias.
ES2413011T3 (es) 2004-02-06 2013-07-15 Meda Pharma Gmbh & Co. Kg Combinación de anticolinérgicos y glucocorticoides para el tratamiento a largo plazo de asma y EPOC
GB0410399D0 (en) 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
EP1616567A1 (fr) 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Médicaments comprenant des inhibiteurs de PDE-IV et des sels de glycopyrolate pour l'inhalation
GB0505545D0 (en) 2005-03-17 2005-04-27 Glaxo Group Ltd Inhalation devices
EP2484382A1 (fr) 2005-03-30 2012-08-08 Schering Corporation Médicament à base d'un inhibiteur de la phosphodiestérase IV sous une forme adaptée à l'inhalation
GB0523653D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
CA2616505A1 (fr) 2005-08-01 2007-02-08 Astrazeneca Ab Valve d'inhalateur
GB0523655D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523654D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523656D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
NZ591969A (en) 2005-12-21 2012-05-25 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-adrenoceptor agonists, PDE 4 inhibitor and antileukotriene for the treatment of inflammatory diseases
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP1894568A1 (fr) * 2006-08-31 2008-03-05 Novartis AG Composées pharmaceutiques destinées au traitement des maladies inflammatoires ou obstructives des bronches
ES2671874T3 (es) 2007-10-18 2018-06-11 Rose U, Llc Formulaciones tópicas de glicopirrolato
AU2010258751A1 (en) * 2009-06-09 2012-02-02 Sunovion Respiratory Development Inc. Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
SG181870A1 (en) * 2009-12-23 2012-07-30 Chiesi Farma Spa Aerosol formulation for copd
EP2515855B3 (fr) * 2009-12-23 2023-05-03 Chiesi Farmaceutici S.p.A. Polythérapie pour la COPD
KR20120106753A (ko) * 2009-12-23 2012-09-26 키에시 파르마슈티시 엣스. 피. 에이. Ｃｏｐｄ용 에어로졸 제제
BR112012015334A2 (pt) * 2009-12-23 2016-03-15 Chiesi Farma Spa terapia combinada para doença pulmonar obstrutiva crônica
RS57799B1 (sr) * 2013-07-11 2018-12-31 Chiesi Farm Spa Formulacija suvog praha za administriranje inhalacijom, koja obuhvata atniholinergik, kortikosteroid i beta-adrenergik
RS57687B1 (sr) 2013-12-30 2018-11-30 Chiesi Farm Spa Pod pritiskom stabilan aerosolni rastvor kompozicije glikopironijum bromida i kombinacije formoterola
GEAP201814192A (en) 2013-12-30 2018-02-26 Chiesi Farm Spa Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
US9554992B2 (en) * 2014-06-09 2017-01-31 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
US10098837B2 (en) * 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD

Also Published As

Publication number Publication date
HRP20140582T1 (hr) 2014-08-01
CY2017047I1 (el) 2018-04-04
KR20120103653A (ko) 2012-09-19
PE20160853A1 (es) 2016-09-14
BR112012015337B1 (pt) 2021-05-04
EA201590179A1 (ru) 2015-09-30
JP2013515696A (ja) 2013-05-09
RS53391B (sr) 2014-10-31
EP2515855B1 (fr) 2014-04-02
US20190046433A1 (en) 2019-02-14
AU2018202998A1 (en) 2018-05-17
EA021917B1 (ru) 2015-09-30
JP6283388B2 (ja) 2018-02-21
TW201129359A (en) 2011-09-01
NL300923I2 (en) 2019-07-22
MX2012006878A (es) 2012-07-04
GEP20156311B (en) 2015-07-10
HK1197036A1 (en) 2015-01-02
EP2515855A2 (fr) 2012-10-31
LTPA2018001I1 (lt) 2018-02-12
SI2515855T1 (sl) 2014-08-29
NL300923I1 (en) 2018-01-17
IL260932B (en) 2021-04-29
CA2785321A1 (fr) 2011-06-30
AU2010334859A1 (en) 2012-07-12
SG181868A1 (en) 2012-07-30
US10159645B2 (en) 2018-12-25
DK2515855T6 (da) 2023-06-06
KR20170040392A (ko) 2017-04-12
PT2515855E (pt) 2014-06-11
LTC2515855I2 (lt) 2019-05-10
CY2017047I2 (el) 2018-04-04
CN104055765A (zh) 2014-09-24
ES2468840T3 (es) 2014-06-17
NO2018001I1 (no) 2018-01-10
HRP20140582T4 (hr) 2023-06-09
EP2515855B3 (fr) 2023-05-03
CL2012001705A1 (es) 2012-09-28
EA201290375A1 (ru) 2013-01-30
AR115897A2 (es) 2021-03-10
BR112012015337A2 (pt) 2016-03-15
CO6541628A2 (es) 2012-10-16
CA2785321C (fr) 2018-08-21
DK2515855T3 (da) 2014-06-30
AU2016234895C1 (en) 2026-02-19
TWI495468B (zh) 2015-08-11
NO2018001I2 (no) 2018-01-10
NZ600790A (en) 2014-09-26
BR112012015337B8 (pt) 2021-05-25
HK1174566A1 (en) 2013-06-14
TN2012000269A1 (en) 2013-12-12
WO2011076843A2 (fr) 2011-06-30
AR079726A1 (es) 2012-02-15
EA027778B1 (ru) 2017-08-31
PL2515855T6 (pl) 2023-12-18
PL2515855T3 (pl) 2014-08-29
FI2515855T6 (fi) 2023-06-02
AU2016234895B2 (en) 2018-02-01
FIC20170064I1 (fi) 2017-12-29
AU2016234895A1 (en) 2016-10-13
JP2016145239A (ja) 2016-08-12
KR101757951B1 (ko) 2017-07-13
CN102665679B (zh) 2014-11-26
JP5914354B2 (ja) 2016-05-11
US20150328144A1 (en) 2015-11-19
WO2011076843A3 (fr) 2011-12-01
PE20121396A1 (es) 2012-10-24
RS53391B2 (sr) 2023-09-29
ES2468840T7 (es) 2023-11-29
LUC00060I2 (fr) 2018-03-16
CY1115116T1 (el) 2016-12-14
PH12012501066A1 (en) 2016-03-02
UA113832C2 (xx) 2017-03-27
CN102665679A (zh) 2012-09-12
HUS1800001I1 (hu) 2018-02-28
CN104055765B (zh) 2016-11-23
ZA201204615B (en) 2013-09-25
US20110150782A1 (en) 2011-06-23
LUC00060I1 (fr) 2018-01-18
MY156949A (en) 2016-04-15
US11389401B2 (en) 2022-07-19

Similar Documents

Publication Publication Date Title
MA33823B1 (fr) Polythérapie pour bronchopneumopathie chronique obstructive (copd)
WO2011076841A3 (fr) Polythérapie destinée à la bronchopneumopathie chronique obstructive
MY143517A (en) Formoterol superfine formulation
HRP20130835T1 (hr) Farmaceutske formulacije otopine za davanje kao stlaäśeni inhalat u inhalatoru
AR101593A2 (es) Formulación superfina de formoterol
MA33821B1 (fr) Préparation aérosol pour copd (bronchopneumathie chronique obstructive)
RU2010108640A (ru) Новая комбинация терапевтических агентов
RU2019100425A (ru) Новая доза и препаративная форма
JP2010132695A5 (fr)
JP2013542940A5 (fr)
RU2013106866A (ru) Фармацевтические композиции
WO2008151235A3 (fr) Procédés et compositions pour administrer des médicaments aux poumons
JP2013531056A5 (fr)
RU2008129600A (ru) Комбинация и фармацевтический препарат для лечения воспалительных заболеваний
CA2550841A1 (fr) Nouvelle combinaison d'anticholinergique et de beta-mimetiques pour le traitement de maladies respiratoires
WO2007137204A3 (fr) Méthodes de distribution d'un agoniste bêta2 pour induire une bronchodilatation et formulations utilisées dans ces procédés
WO2010068754A3 (fr) Procédés et compositions pour la délivrance de médicaments aux poumons
JP2019528316A5 (fr)
NO20051956L (no) Salmeterol superfin formulering
MX2023001201A (es) Terapia combinada para la administracion por inhalacion.
MX2023003754A (es) Formulacion farmaceutica para inhalador presurizado de dosis medidas.
JO3024B1 (ar) صيغ أيروسول صيدلانية من الفرموتيرول وبكلوميتازون داي بروبيونات
Plaunt et al. Structure Dependent PK Profiles Of Alkyl Ester Treprostinil Prodrugs (TPD) Administrated Via Metered Dose Inhaler To Rats